Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Savani, Bipin N  [Clear All Filters]
2020
Mohty, M., Duléry, R., Gauthier, J., Malard, F., Brissot, E., Aljurf, M., Bazarbachi, A., Chabanon, C., Kharfan-Dabaja, M.A., Savani, B.N., et al. (2020). CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview.Bone Marrow Transplant.
Maffini, E., Labopin, M., Blaise, D., Ciceri, F., Gulbas, Z., Deconinck, E., Leblond, V., Chevallier, P., Socié, G., Araujo, M.Colorado, et al. (2020). CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European.Am J Hematol.
Hsu, J.W., Shaw, B.E., Kim, S., Logan, B.R., Sees, J.A., Confer, D.L., Pulsipher, M.A., Shah, N., Switzer, G.E., Abidi, M.H., et al. (2020). Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors.Biol Blood Marrow Transplant.
Mehta, R.S., Holtan, S.G., Wang, T., Hemmer, M.T., Spellman, S.R., Arora, M., Couriel, D.R., Alousi, A.M., Pidala, J., Abdel-Azim, H., et al. (2020). Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.J Clin OncolJCO1900396.
Gowin, K., Ballen, K., Ahn, K.Woo, Hu, Z.-H., Ali, H., Arcasoy, M.O., Devlin, R., Coakley, M., Gerds, A.T., Green, M., et al. (2020). Survival following allogeneic transplant in patients with myelofibrosis.Blood Adv4, 1965-1973.
2019
Cohen, J.A., Baldassari, L.E., Atkins, H.L., Bowen, J.D., Bredeson, C., Carpenter, P.A., Corboy, J.R., Freedman, M.S., Griffith, L.M., Lowsky, R., et al. (2019). AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION.Biol Blood Marrow Transplant.
Kilari, D., D'Souza, A., Fraser, R., Qayed, M., Davila, O., Agrawal, V., Díaz, M.Ángel, Chhabra, S., Cerny, J., Copelan, E., et al. (2019). Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades.Biol Blood Marrow Transplant.
Zinter, M.S., Logan, B.R., Fretham, C., Sapru, A., Abraham, A., Aljurf, M.D., Arnold, S.D., Artz, A., Auletta, J.J., Chhabra, S., et al. (2019). Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.Biol Blood Marrow Transplant.
Prokopishyn, N.L., Logan, B.R., Kiefer, D.M., Sees, J.A., Chitphakdithai, P., Ahmed, I.A., Anderlini, P.N., Beitinjaneh, A.M., Bredeson, C., Cerny, J., et al. (2019). The concentration of total nucleated cells in harvested bone marrow for transplantation has decreased over time.Biol Blood Marrow Transplant.
DeFilipp, Z., Advani, A.S., Bachanova, V., Cassaday, R.D., DeAngelo, D.J., Kebriaei, P., Rowe, J.M., Seftel, M.D., Stock, W., Tallman, M.S., et al. (2019). Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.Biol Blood Marrow Transplant.
Santoro, N., Labopin, M., Ciceri, F., van Lint, M.Teresa, Nasso, D., Blaise, D., Arcese, W., Tischer, J., Bruno, B., Ehninger, G., et al. (2019). Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age.Cancer.
Hamilton, B.K., Liu, Y., Hemmer, M.T., Majhail, N., Ringdén, O., Kim, D., Costa, L., Stuart, R., Alousi, A., Pidala, J.A., et al. (2019). Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.
Buchbinder, D., Brazauskas, R., Bo-Subait, K., Ballen, K., Parsons, S., John, T., Hahn, T., Sharma, A., Steinberg, A., D'Souza, A., et al. (2019). Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research.Biol Blood Marrow Transplant.
Nagler, A., Labopin, M., Dholaria, B., Finke, J., Brecht, A., Schanz, U., Niittyvuopio, R., Neubauer, A., Bornhäuser, M., Santarone, S., et al. (2019). Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.Br J Haematol.
Naik, S., Riches, M., Hari, P., Soyoung, K., Chen, M., Bachier, C., Shaughnessy, P., Hill, J., Ljungman, P., Battiwalla, M., et al. (2019). Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study.Transpl Infect Dise13145.
Adkins, B.D., Savani, B.N., and Booth, G.S. (2019). Transgender individuals represent an overlooked population amongst stem cell donors.Bone Marrow Transplant.
2018
Kansagra, A.J., Frey, N.V., Bar, M., Laetsch, T.W., Carpenter, P.A., Savani, B.N., Heslop, H.E., Bollard, C.M., Komanduri, K.V., Gastineau, D.A., et al. (2018). Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl.Biol Blood Marrow Transplant.
Chhabra, S., Liu, Y., Hemmer, M.T., Costa, L., Pidala, J.A., Couriel, D.R., Alousi, A.M., Majhail, N.S., Stuart, R.K., Kim, D., et al. (2018). Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation.Biol Blood Marrow Transplant.
Lee, C.J., Labopin, M., Beelen, D., Finke, J., Blaise, D., Ganser, A., Itälä-Remes, M., Chevallier, P., Labussière-Wallet, H., Maertens, J., et al. (2018). Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT.Am J Hematol.
Gilleece, M.H., Labopin, M., Yakoub-Agha, I., Volin, L., Socié, G., Ljungman, P., Huynh, A., Deconinck, E., Wu, D., Bourhis, J.Henri, et al. (2018). Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu.Am J Hematol.
Inamoto, Y., Petriček, I., Burns, L., Chhabra, S., DeFilipp, Z., Hematti, P., Rovó, A., Schears, R., Shah, A., Agrawal, V., et al. (2018). Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.Biol Blood Marrow Transplant.
Inamoto, Y., Valdés-Sanz, N., Ogawa, Y., Alves, M., Berchicci, L., Galvin, J., Greinix, H., Hale, G.A., Horn, B., Kelly, D., et al. (2018). Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.Biol Blood Marrow Transplant.
Gopalakrishnan, S., D'Souza, A., Scott, E., Fraser, R., Davila, O., Shah, N., Gale, R.Peter, Kamble, R., Díaz, M.Ángel, Lazarus, H.M., et al. (2018). Revised-International Staging System (R-ISS) is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma (MM)..Biol Blood Marrow Transplant.
Radivoyevitch, T., Dean, R.M., Shaw, B.E., Brazauskas, R., Tecca, H.R., Molenaar, R.J., Battiwalla, M., Savani, B.N., Flowers, M.E.D., Cooke, K.R., et al. (2018). Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.Leuk Res.

Pages